Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$20.69 USD
+0.18 (0.88%)
Updated May 17, 2024 04:00 PM ET
After-Market: $20.70 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
Longboard Pharmaceuticals, Inc. [LBPH]
Reports for Purchase
Showing records 1 - 20 ( 57 total )
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Digging In Deeper To PACIFIC Data -- Detailed Results Presented
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AAN Takeaway: Full PACIFIC Dataset Supports Advancement of Bexicaserin to Phase 3 in Epilepsy by End-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lead Bexicaserin Phase 3 Program in Epilepsy to Start by End-2024; 4Q23 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Moving Full Speed Ahead Toward Pivotal Phase 3 Program on Potential Blockbuster Bexicaserin in Epilepsy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Robust Phase 2 Data in Lead Epilepsy Program Support Advancement to Phase 3; Raising Price Target to $60; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catching A Good Wave With PACIFIC Data - Layering In The Offering
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PACIFIC Delivers For LBPH and Bexicaserin (LP352); Top-Line Results, Takeaways
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
What Will 2024 Bring? LP352 PACIFIC Data To Start; Thoughts Into The Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for LBPH 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Longboard Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Top-line Phase 2 Data with Lead GPCR Program in Epilepsy Expected January 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P